749 related articles for article (PubMed ID: 11773888)
1. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection.
Sollinger H; Kaplan B; Pescovitz MD; Philosophe B; Roza A; Brayman K; Somberg K
Transplantation; 2001 Dec; 72(12):1915-9. PubMed ID: 11773888
[TBL] [Abstract][Full Text] [Related]
2. Rabbit antithymocyte globulin versus basiliximab in renal transplantation.
Brennan DC; Daller JA; Lake KD; Cibrik D; Del Castillo D;
N Engl J Med; 2006 Nov; 355(19):1967-77. PubMed ID: 17093248
[TBL] [Abstract][Full Text] [Related]
3. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
Yang SL; Wang D; Wu WZ; Lin WH; Xu TZ; Cai JQ; Tan JM
Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938
[TBL] [Abstract][Full Text] [Related]
4. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.
Thomusch O; Wiesener M; Opgenoorth M; Pascher A; Woitas RP; Witzke O; Jaenigen B; Rentsch M; Wolters H; Rath T; Cingöz T; Benck U; Banas B; Hugo C
Lancet; 2016 Dec; 388(10063):3006-3016. PubMed ID: 27871759
[TBL] [Abstract][Full Text] [Related]
5. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids.
Mourad G; Rostaing L; Legendre C; Garrigue V; Thervet E; Durand D
Transplantation; 2004 Aug; 78(4):584-90. PubMed ID: 15446319
[TBL] [Abstract][Full Text] [Related]
6. A single center's clinical experience with quadruple immunosuppression including ATG or IL2 antibodies and mycophenolate mofetil in simultaneous pancreas-kidney transplants.
Hesse UJ; Troisi R; Jacobs B; Van Vlem B; de Hemptinne B; Van Holder R; Vermassen F; De Roose J; Lameire N
Clin Transplant; 2000 Aug; 14(4 Pt 1):340-4. PubMed ID: 10945205
[TBL] [Abstract][Full Text] [Related]
7. Anti-thymocyte globulin versus basiliximab induction in renal transplant recipients: Long-term outcome.
Kesiraju S; Paritala P; Rao Ch UM; Athmakuri SM; Reddy VS; Sahariah S
Saudi J Kidney Dis Transpl; 2014 Jan; 25(1):9-15. PubMed ID: 24434376
[TBL] [Abstract][Full Text] [Related]
8. Basiliximab: a review of its use as induction therapy in renal transplantation.
Chapman TM; Keating GM
Drugs; 2003; 63(24):2803-35. PubMed ID: 14664658
[TBL] [Abstract][Full Text] [Related]
9. Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy.
Mattei MF; Redonnet M; Gandjbakhch I; Bandini AM; Billes A; Epailly E; Guillemain R; Lelong B; Pol A; Treilhaud M; Vermes E; Dorent R; Lemay D; Blanc AS; Boissonnat P
J Heart Lung Transplant; 2007 Jul; 26(7):693-9. PubMed ID: 17613399
[TBL] [Abstract][Full Text] [Related]
10. Induction treatment with rabbit antithymocyte globulin versus basiliximab in renal transplant recipients with planned early steroid withdrawal.
Martin ST; Roberts KL; Malek SK; Tullius SG; Vadivel N; De Serres S; Grafals M; Elsanjak A; Filkins BA; Chandraker A; Gabardi S
Pharmacotherapy; 2011 Jun; 31(6):566-73. PubMed ID: 21923440
[TBL] [Abstract][Full Text] [Related]
11. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group.
Kahan BD; Rajagopalan PR; Hall M
Transplantation; 1999 Jan; 67(2):276-84. PubMed ID: 10075594
[TBL] [Abstract][Full Text] [Related]
12. A multicenter, open-label, pharmacokinetic/pharmacodynamic safety, and tolerability study of basiliximab (Simulect) in pediatric de novo renal transplant recipients.
Offner G; Broyer M; Niaudet P; Loirat C; Mentser M; Lemire J; Crocker JF; Cochat P; Clark G; Chodoff L; Korn A; Hall M
Transplantation; 2002 Oct; 74(7):961-6. PubMed ID: 12394837
[TBL] [Abstract][Full Text] [Related]
13. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
Clark G; Walsh G; Deshpande P; Koffman G
Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients.
Ponticelli C; Yussim A; Cambi V; Legendre C; Rizzo G; Salvadori M; Kahn D; Kashi H; Salmela K; Fricke L; Heemann U; Garcia-Martinez J; Lechler R; Prestele H; Girault D;
Transplantation; 2001 Oct; 72(7):1261-7. PubMed ID: 11602853
[TBL] [Abstract][Full Text] [Related]
15. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.
Nashan B; Moore R; Amlot P; Schmidt AG; Abeywickrama K; Soulillou JP
Lancet; 1997 Oct; 350(9086):1193-8. PubMed ID: 9652559
[TBL] [Abstract][Full Text] [Related]
16. A retrospective comparison of the efficacy and safety in kidney transplant recipients with basiliximab and anti-thymocyte globulin.
Wang W; Yin H; Li XB; Hu XP; Yang XY; Liu H; Ren L; Wang Y; Zhang XD
Chin Med J (Engl); 2012 Mar; 125(6):1135-40. PubMed ID: 22613543
[TBL] [Abstract][Full Text] [Related]
17. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
[TBL] [Abstract][Full Text] [Related]
18. Rabbit antithymocyte globulin compared with basiliximab in kidney transplantation: a single-center study.
Kim JM; Jang HR; Kwon CH; Huh WS; Kim GS; Kim SJ; Joh JW; Oh HY
Transplant Proc; 2012 Jan; 44(1):167-70. PubMed ID: 22310606
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids.
Offner G; Toenshoff B; Höcker B; Krauss M; Bulla M; Cochat P; Fehrenbach H; Fischer W; Foulard M; Hoppe B; Hoyer PF; Jungraithmayr TC; Klaus G; Latta K; Leichter H; Mihatsch MJ; Misselwitz J; Montoya C; Müller-Wiefel DE; Neuhaus TJ; Pape L; Querfeld U; Plank C; Schwarke D; Wygoda S; Zimmerhackl LB
Transplantation; 2008 Nov; 86(9):1241-8. PubMed ID: 19005406
[TBL] [Abstract][Full Text] [Related]
20. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy.
Lebranchu Y; Bridoux F; Büchler M; Le Meur Y; Etienne I; Toupance O; Hurault de Ligny B; Touchard G; Moulin B; Le Pogamp P; Reigneau O; Guignard M; Rifle G
Am J Transplant; 2002 Jan; 2(1):48-56. PubMed ID: 12095056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
